Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Androtriol Injection for Intracerebral Hemorrhage
ChiCTR2600119554Phase 2Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of androtriol in intracerebral hemorrhage (ICH) (3 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Proportion of mRS 0–1 at 90±7 days after administration. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
androtriol
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR2600119554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119554.